An update on beta-lactam–beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant Gram-negative pathogens

Expert Opinion on Drug Metabolism and Toxicology · Published 2026-06-19 · DOI 10.1080/17425255.2026.2691051

Free full text

Authors (11)

Ilias Karaiskos, Aikaterini Gkoufa, Evdoxia Kyriazopoulou, Eleni Polyzou, Vasiliki Rapti, Konstantinos Ioannidis, Evangelia Chrysanthopoulou, Zoe Athanassa, Karolina Akinosoglou, Garyphalia Poulakou, On behalf of the Study Group of the Hellenic Group for the Combat of Antimicrobial Resistance in Critically Ill Patients of the Hellenic Society of Chemotherapy

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Karaiskos, I., Gkoufa, A., Kyriazopoulou, E., et al. (2026). An update on beta-lactam–beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opinion on Drug Metabolism and Toxicology. https://doi.org/10.1080/17425255.2026.2691051

Related articles

• Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance · Expert Opinion on Drug Metabolism and Toxicology · 2025 · Same journal
• Microbiome-driven PKs: redefining drug metabolism beyond host enzymes · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Combined oral contraceptives and pharmacokinetic drug interactions: impact on efficacy and safety · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Predicting the potential for organic cation transporter 1-mediated drug–drug interactions with fenoterol by amitriptyline, fluoxetine, selegiline, metformin, and verapamil · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Pharmacokinetics and safety of the combination of KL130008 and methotrexate in rheumatoid arthritis patients: a multicenter, open-label phase Ib trial · Expert Opinion on Drug Metabolism and Toxicology · 2025 · Same journal
• Evaluation of the drug-drug interaction between low-dose methotrexate and short-term use of non-steroidal anti-inflammatory drugs · Expert Opinion on Drug Metabolism and Toxicology · 2025 · Same journal
• GLP-1RA PHARMACOKINETICS AND CLINICAL EFFECTS: FOCUS ON CARDIAC, VASCULAR, AND GLOMERULAR STRUCTURES · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Modifying Hy’s Law and eDISH for the modern idiosyncratic DILI era · Expert Opinion on Drug Metabolism and Toxicology · 2025 · Same journal
• Exploring the influence of sex on idiosyncratic DILI: impact on risk assessment · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal
• Complex in vitro model developers’ perspective on advanced hepatic in vitro culture methods for predictive drug safety · Expert Opinion on Drug Metabolism and Toxicology · 2026 · Same journal